argenx_logo_default.png
argenx Enters Into Agreement To Acquire Priority Review Voucher
November 30, 2022 01:00 ET | argenx SE
Amsterdam, the Netherlands – November 30, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx_logo_default.png
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
November 22, 2022 01:00 ET | argenx SE
- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023 - Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at...
argenx_logo_default.png
argenx to Present at Upcoming Investor Conferences
November 07, 2022 01:00 ET | argenx SE
November 7, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx_logo_default.png
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022 01:00 ET | argenx SE
$131 million in third quarter VYVGART® (efgartigimod alfa-fcab) global net product sales Filed Biologics License Application (BLA) for subcutaneous (SC) efgartigimod for treatment of generalized...
argenx_logo_default.png
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
October 20, 2022 01:00 ET | argenx SE
October 20, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx_logo_default.png
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
September 21, 2022 01:00 ET | argenx SE
Scientific presentations demonstrate argenx’s leadership in FcRn blockade and commitment to innovating for patients across multiple neuromuscular diseases Additional data from ADAPT+ open-label study...
argenx_logo_default.png
argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
September 21, 2022 01:00 ET | argenx SE
Submission package based on positive data from the Phase 3 ADAPT-SC trial demonstrating noninferiority of subcutaneous (SC) efgartigimod compared to intravenously administered VYVGART® (efgartigimod...
argenx_logo_default.png
argenx Appoints Camilla Sylvest to Board of Directors
September 08, 2022 14:10 ET | argenx SE
September 8, 2022 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx_logo_default.png
argenx to Present at Wells Fargo Healthcare Conference
August 31, 2022 01:00 ET | argenx SE
August 31, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx_logo_default.png
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
August 11, 2022 07:00 ET | argenx SE
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR)...